Evidence map›Paper›PMID 42360378›Full record

ArticleLangenbeck's archives of surgery2026

AI-assisted digital breast tomosynthesis as a decision-support tool for post-neoadjuvant surgical planning in breast cancer.

Adnan Gündoğdu, Nur Betül Ünal Özdemir, Ceyda Sönmez Wetherilt, Merve Aktaş, Damiano Gentile, Bülent Çomçalı, Osman Cem Yılmaz

Abstract read
In one paragraph

Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adnan GündoğduDepartment of General Surgery, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Türkiye. adnangundogdu89@gmail.com.ORCID http://orcid.org/0000-0003-2341-3572
Nur Betül Ünal ÖzdemirDepartment of Radiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Türkiye.ORCID http://orcid.org/0000-0001-7917-3534
Ceyda Sönmez WetheriltDepartment of Medical Pathology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.ORCID http://orcid.org/0009-0002-5252-479X
Merve AktaşDepartment of Surgical Oncology, Sakarya University Training and Research Hospital, Sakarya, Türkiye.ORCID http://orcid.org/0000-0002-1108-8752
Damiano GentileBreast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID http://orcid.org/0000-0002-8861-5223
Bülent ÇomçalıDepartment of General Surgery, Ankara Bilkent City Hospital, Ankara, Türkiye.ORCID http://orcid.org/0000-0002-2111-1477
Osman Cem YılmazBreast Surgery, Istanbul Breast Center, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-8418-0234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAccurate assessment of residual disease after neoadjuvant chemotherapy (NAC) is essential for surgical planning and prevention of incomplete excision. This study evaluated artificial intelligence (AI)-assisted digital breast tomosynthesis (DBT) as a decision-support tool for post-NAC assessment in breast cancer.

methodsThis retrospective study included 151 patients treated with NAC followed by surgery. Post-NAC DBT images were analyzed using Lunit INSIGHT DBT. An AI score threshold of 70 was used to classify patients as having low (< 70) or high (≥ 70) scores. In a paired subgroup of 70 patients, pre- and post-NAC AI scores were compared. Diagnostic performance and univariable and multivariable analyses were performed.

resultsThe overall pathological complete response (pCR) rate was 41.1% (62/151). Patients with low AI scores had higher pCR rates than those with high scores (49.5% vs. 28.3%, p = 0.010). High AI scores were associated with persistent microcalcifications and residual ductal carcinoma in situ (p < 0.001). Overall accuracy was 58.3% and varied by molecular subtype, with higher performance in triple-negative breast cancer and limited discrimination in HR+/HER2 - tumors. In multivariable analysis, AI score showed borderline significance (p = 0.070). In the paired cohort, AI scores decreased after NAC (p < 0.001), but delta change did not differ between pCR and non-pCR groups (p = 0.877).

conclusionAI-assisted DBT may have potential complementary value as a decision-support tool for post-NAC surgical planning, particularly in triple-negative breast cancer and in cases with residual microcalcifications.

Indexed as

Artificial IntelligenceBreast NeoplasmsDecision Support TechniquesMammographyAdultAgedFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualPathologic Complete ResponseRetrospective StudiesArtificial intelligenceBreast neoplasmsDigital breast tomosynthesisNeoadjuvant chemotherapyTreatment response

Identifiers

PMID42360378
PMCPMC13572336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.